Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: A French national multicenter study (FRANCOGYN).
Fiche publication
Date publication
décembre 2019
Journal
European journal of obstetrics, gynecology, and reproductive biology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BALDAUF Jean-Jacques, Pr COUTANT Charles, Pr VELTEN Michel, Dr DEMARCHI Martin, Dr GANTZER Justine
Tous les auteurs :
Lecointre L, Velten M, Lodi M, Saadeh R, Lavoué V, Ouldamer L, Bendifallah S, Koskas M, Bolze PA, Collinet P, Canlorbe G, Touboul C, Huchon C, Coutant C, Faller E, Boisramé T, Gantzer J, Martin D, Baldauf JJ, Akladios C, Ballester M
Lien Pubmed
Résumé
The purpose of this study was to compare two groups of patients presenting advanced ovarian carcinoma benefiting from neoadjuvant chemotherapy (NAC) followed by cytoreductive surgery: after 3-4 cycles (group 1) or ≥ 5 cycles (group 2), regarding overall survival (OS) and progression-free survival (PFS), complications related to surgery as well as the extent of cytoreduction were assessed.
Mots clés
Cytoreductive surgery, Neoadjuvant chemotherapy, Ovarian cancer, Surgical complications, Survival
Référence
Eur. J. Obstet. Gynecol. Reprod. Biol.. 2019 Dec 6;245:64-72